US2022227881A1PendingUtilityA1
Humanized Monoclonal Antibody Targeting Pro-N-Cadherin
Est. expiryApr 5, 2039(~12.7 yrs left)· nominal 20-yr term from priority
C07K 16/2896A61P 1/16C07K 2317/24C07K 2317/31C07K 2317/73C07K 2317/565
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Humanized antibody to a pathologically mislocated form of N-cadherin detects and eliminates cells that express the protein extracellularly. These cells are found in fibrotic conditions within heart, lung, and liver, as well as kidney, skin, and other organs effected by fibrosis. The antibody does not affect cells with normal, subcellular location of the protein.
Claims
exact text as granted — not AI-modified1 .- 4 . (canceled)
5 . A polynucleotide encoding a humanized antibody which binds to pro-N-cadherin in its pro-domain, said polynucleotide comprising:
segments encoding framework portions of a human antibody; and segments encoding six complementarity determining regions (CDRs) from a mouse antibody, wherein the CDRs are SEQ ID NO: 22-27 or SEQ ID NO: 28-33.
6 . The polynucleotide of claim 5 wherein the segments encoding the six CDRs are SEQ ID NO: 5-10 or SEQ ID NO: 11-16.
7 . The polynucleotide of claim 5 wherein the human antibody is an IgG1 antibody.
8 . The polynucleotide of claim 5 that is in a replicating vector.
9 . The polynucleotide of claim 5 that is codon optimized for expression in cells of a non-human species.
10 .- 19 . (canceled)Join the waitlist — get patent alerts
Track US2022227881A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.